highperformr logo

Cytokinetics's Overview

Total employees570
HeadquartersSouth San Francisco
Founded1998

Cytokinetics is a pioneering late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel muscle-directed therapies. With a deep understanding of muscle biology and the mechanics of muscle performance, Cytokinetics focuses on creating first-in-class and best-in-class treatments for diseases characterized by impaired muscle function, such as heart failure, hypertrophic cardiomyopathy (HCM), and amyotrophic lateral sclerosis (ALS). Their innovative approach targets muscle contractility to improve the health span of patients with debilitating conditions.

Where is Cytokinetics's Headquarters?

HQ Function

Serves as the central hub for research and development, corporate operations, clinical development, and strategic decision-making for its global activities.

Notable Features:

State-of-the-art laboratory facilities equipped for advanced muscle biology research, collaborative office spaces designed to foster innovation, and proximity to a rich ecosystem of biotech peers and academic institutions.

Work Culture:

Characterized by a science-driven, patient-focused environment that encourages collaboration, innovation, scientific rigor, and a collective commitment to addressing unmet medical needs in severe diseases.

HQ Significance:

The South San Francisco location places Cytokinetics at the epicenter of biopharmaceutical innovation, facilitating access to top-tier talent, leading research institutions, and key industry partners, crucial for its R&D and commercial aspirations.

Values Reflected in HQ: The headquarters' design and operations reflect Cytokinetics' core values of scientific excellence, integrity, patient-centricity, and teamwork in its pursuit of transformative medicines.

Location:

While headquartered in the U.S., Cytokinetics maintains a global outlook, primarily through its extensive clinical trial operations conducted across North America, Europe, Asia, and other regions. The company is actively preparing for potential global commercialization of its late-stage drug candidates and engages with international regulatory bodies, research collaborators, and patient advocacy groups worldwide. Its strategy includes building infrastructure to support potential international product launches and market access.

Street Address:

350 Oyster Point Boulevard

City:

South San Francisco

State/Province:

CA

Country:

USA

Cytokinetics's Global Presence

Buying Intent Signals for Cytokinetics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Cytokinetics

As of April 2025, Cytokinetics' leadership includes:

Robert I. Blum - President and Chief Executive Officer
Fady I. Malik, M.D., Ph.D. - Executive Vice President of Research and Development
Ching Jaw, M.B.A., C.P.A. - Executive Vice President, Chief Financial Officer and Chief Business Officer
Stuart Kupfer, M.D., FACC - Executive Vice President and Chief Medical Officer
Lisa Domingo - Executive Vice President, Chief People and Culture Officer
Robert C. McDowell, Ph.D. - Executive Vice President, Commercial Strategy & Operations
Andrew Callos - Chief Commercial Officer

Investors of Cytokinetics

Cytokinetics has been backed by several prominent investors over the years, including:

BlackRock Inc.
The Vanguard Group, Inc.
RTW Investments, LP
Perceptive Advisors LLC
State Street Corporation
Deep Track Capital, LP
RA Capital Management

Executive New Hires/Exits in the Last 12 Months

Hire3
Exits0

Over the past 12 months, Cytokinetics has significantly bolstered its executive leadership, particularly in commercial and people operations, gearing up for potential product launches and organizational growth. Key appointments include a new Chief Commercial Officer, an EVP of Commercial Strategy & Operations, and an EVP, Chief People and Culture Officer. No high-profile executive departures were publicly announced during this period.

New Appointments:

Andrew Callos, Andrew Callos appointed as Chief Commercial Officer to lead commercialization efforts for aficamten and future products.
Lisa Domingo, Lisa Domingo appointed as EVP, Chief People and Culture Officer to lead human resources and organizational development.
Robert C. McDowell, Ph.D., Robert C. McDowell appointed as EVP, Commercial Strategy & Operations to spearhead commercial readiness.

Technology (Tech Stack) used by Cytokinetics

Discover the tools Cytokinetics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Cytokinetics Email Formats and Examples

Cytokinetics, Inc. most commonly utilizes the email format combining the first initial of an employee's name with their full last name, followed by '@cytokinetics.com'. This is a standard professional email structure within the biopharmaceutical industry.

flast@cytokinetics.com

Format

rblum@cytokinetics.com

Example

90%

Success rate

News and media

Cytokinetics Investor RelationsMay 7, 2024

Cytokinetics Announces First Quarter 2024 Financial Results

Cytokinetics reported its financial results for the first quarter of 2024, providing updates on its cash position, R&D expenditures, and progress on its pipeline, particularly aficamten....more

Cytokinetics Investor RelationsFebruary 13, 2024

FDA Extends Review Period for Cytokinetics' Aficamten NDA by Three Months

The U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) target action date by three months for the New Drug Application (NDA) for aficamten, for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM), to November 30, 2024....more

Cytokinetics Investor RelationsDecember 27, 2023

Cytokinetics Announces Positive Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

Cytokinetics announced that SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten, met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in exercise capacity for patients with oHCM....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Cytokinetics, are just a search away.